Man thinking

Lenabasum receives Orphan Drug Designation for DM

Corbus Pharmaceuticals recently announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to lenabasum, its novel, synthetic oral endocannabinoidmimetic drug, for the treatment of dermatomyositis, systemic sclerosis, and other conditions.

Continue Reading